Arcutis Biotherapeutics, Inc.
ARQT
Kedudukan dalam Saham
#3980
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Harga Saham
$32.88
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$4.13B
Perubahan (1 hari)
3.11%
Perubahan (1 tahun)
59.32%
Negara
US
Perdagangan Arcutis Biotherapeutics, Inc. (ARQT)
Kategori
Healthcare
Hasil untuk Arcutis Biotherapeutics, Inc. (ARQT)
Hasil pada Jun 2026 TTM: $463.98M
Menurut laporan kewangan terkini daripada Arcutis Biotherapeutics, Inc., hasil semasa syarikat (TTM) ialah $463.98M. Pada tahun 2023, syarikat memperoleh hasil sebanyak $59.61M peningkatan berbanding hasil pada tahun 2022 iaitu $3.69M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Arcutis Biotherapeutics, Inc. dari 2017 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $463.98M | 136.07% |
| 2024 | $196.54M | 229.74% |
| 2023 | $59.61M | 1,517.09% |
| 2022 | $3.69M | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 2,620.87% |
US
|
|
| $2.23B | 380.19% |
US
|
|
| $15.74B | 3,293.31% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 1,197.74% |
NL
|
